BRAF and melanoma: As such, three BRAF/MEK combination therapy options are recommended by the most recent (2020) ASCO guidelines on systemic therapy for BRAF-mutant metastatic or unresectable melanoma: dabrafenib/trametinib [38,39], encorafenib/binimetinib, or vemurafenib/cobimetinib.